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Background: Osteopontin (OPN) is one of important molecular targets in cancer progression, metastasis as a
calcium-binding, extracellular-matrix-associated protein of the small integrin-binding ligand and, N-linked glycoprotein.
In the present study, anti-metastatic mechanism of ethanol extracts of Ocimum sanctum (EEOS) was elucidated on OPN
enhanced metastasis in NCI-H460 non- small cell lung cancer cells.
Methods: Cell viability was measured by MTT assay. Adhesion and invasion assays were carried out to see that EEOS
inhibited cell adhesion and invasion in OPN treated and non-treated NCI-H 460 cells. RT-PCR was used to determine
the mRNA levels of uPA, uPAR, and EGFR.
Results: EEOS significantly inhibited cell adhesion and invasion in OPN treated and non treated NCI-H460 cells, though
EEOS did not show any toxicity up to 200 μg/ml. EEOS effectively attenuated the expression of OPN and CD44 and also
OPN activated the expression of CD44 in NCI-H460 cells. In addition, EEOS effectively suppressed the expression of
phosphatidylinositide 3-kinases (PI3K) and cyclooxygenase 2 (COX-2) and the phosphorylation of Akt at protein level in
OPN treated NCI-H460 cells. Also, EEOS significantly attenuated the expression of urokinase plasminogen activator
(uPA), its receptor (uPAR) and epidermal growth factor receptor (EGFR) at mRNA level and reduced vascular endothelial
growth factor (VEGF) production and MMP-9 activity in OPN treated NCI-H460 cells. Furthermore, PI3K/Akt inhibitor
LY294002 enhanced anti-metastatic potential of EEOS to attenuate the expression of uPA and MMP-9 in OPN treated
NCI-H 460 cells.
Conclusion: Overall, our findings suggest that anti-metastatic mechanism of EEOS is mediated by inhibition of PI3K/Akt
in OPN treated NCI-H460 non-small cell lung cancer cells.
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Metastasis, one of malignant tumor features, is controlled
by multi-step processes including tumor angiogenesis,
tumor invasion, and establishment metastatic foci at the
secondary site via various molecular targets [1,2].
Osteopontin (OPN) is a secreted phosphorylated
glycoprotein that is closely involved in inflammation
[3,4], kidney stone formation [5,6], tumor migration
and metastasis [7-9]. Also, it was well documented that* Correspondence: sungkim7@khu.ac.kr
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unless otherwise stated.activation of matrix metalloproteinase (MMP)-2 and −9 as
a proteolytic enzyme in extra cellular matrix (ECM) [10]
and urokinase plasminogen activator (uPA) [11,12] and its
receptor (uPAR) [13] is closely involved in metastasis and
cancer invasion. In addition, P13K/Akt pathway was
known to play a key role in cancer metastasis in cholan-
giocarcinoma [14], liver cancer [15], colorectal cancer
[16], lung cancer [17], esophageal cancer [18] and ovarian
cancer [19].
Recently many medicinal herbs [20,21] and phyto-
chemicals [15,22-24] are attractive with anti-metastatic
potential with low toxicity. Ocimum sanctum Linne,
commonly known as ‘Holy basil’, [25] was known to havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kwak et al. BMC Complementary and Alternative Medicine 2014, 14:419 Page 2 of 10
http://www.biomedcentral.com/1472-6882/14/419multi-biological effects on immunomodulation, anti-ulcer,
anti-inflammation and anti-carcinogenesis [26-29]. Fur-
thermore, the ethanol (70%) extract of O. sanctum possess
anti-hyperglycaemic action [30] and anti-fatigue property
in rats [31].
Though our group previously reported ethanol extract
(95%) of OS (EEOS) exerts anti-metastatic activity via
inhibition of MMP-9 and enhancement of antioxidant
enzymes [32], the underlying anti-metastatic mechan-
ism of EEOS still remains unclear. Thus, in the present
study, anti-metastatic mechanism of EEOS was eluci-
dated via cell viability assay, cell adhesion and invasion
assays, ELISA for MMP-9, RT-PCR for uPA, uPAR and
EGFR, Western blotting for osteopontin (OPN), and
CD44, ELISA for VEGF and PI3K/Akt inhibitor LY294002




O.sanctum Linne collected in Chennai, India was identi-
fied by Dr. Namin Baek, a professor and pharmacognos-
ist at Kyung hee University, Korea and stored at the
Cancer Preventive Material Development Research Center
(CPMDRC), Kyung hee University at Korea. The extraction
of O. sanctum Linne was carried out according to standard
protocols as described previously [32]. To extract the
EEOS, 95% ethanol was added in the leaves of O. sanctum
Linne (3 kg) and incubated for 3 days at room temperature.
A rotary evaporator (Eyela, Tokyo, Japan) was used to con-
centrate and freeze-dried to obtain 570 g (yield = 19%) of
ethanol extract of O. sanctum (EEOS).
Cell culture
NCI-H460 non-small cell lung cancer cells (HTB-177™)
were purchased from American Type Culture Collec-
tion (ATCC) and were cultured in RPMI1640 medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
FBS, 2 mM L-glutamine, and 100 units/ml antibiotic-
antimycotics.
Cytotoxicity assay
The cell viability was assessed by MTT assay (Sigma
Chemical Co., St. Louis, MO). NCI-H460 cells were
seeded at 1 × 104 cells/well of 96-well flat bottom plate
and treated with various concentrations of EEOS (0, 6,
12.5, 25, 50, 100, and 200 μg/ml) for 24 h. MTT reagent
was added to each well and incubated for 4 h at 37°C.
Formazen crystals were dissolved by addition of di-
methyl sulfoxide (DMSO) solution. The absorbance of
each well was determined using the microplate reader
(Molecular Devices Co., Sunnyvale, CA, USA) at 570 nm.
Cell viability of H460 cells was calculated as a percentage
of viable cells in EEOS treated group versus control groupby a following equation. Cell viability (%) = [OD (EEOS) -
OD (Blank)] / [ OD (Control) – OD (Blank)] × 100.
Adhesion assay
Adhesion assay was performed as previously described
[33]. Each well of 96-well plate was coated with Matrigel
(11 mg/ml of stock solution) or 0.1% gelatin and incu-
bated for 2 h. The plates were washed and incubated for
1 h with 0.1% bovine serum albumin (BSA) to block un-
bounded surface. Prior to addition of the cells to each
well, OPN treated NCI-H 460 cells (1 × 106) were pre-
incubated with EEOS (0, 100 and 200 μg/ml) for 20 min
at 37°C. A tetrazolium salt, 2,3-bis[2-methyloxy-4-nitro-
5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT)
working solution was prepared just prior to culture appli-
cation by mixing 1 ml of XTT stock solution (1 mg/ml in
phosphate buffered saline (PBS)) with 10 μl of phenazine
methosulphate (PMS) (1.53 mg/ml in PBS). After incuba-
tion at 37°C in a humidified incubator for 24 h, a 50 μl of
XTT working solution was added to each well. Cells were
incubated at 37°C for 2 h and the optical density was mea-
sured by microplate reader (Sunrise, TECAN, Männedorf,
Switzerland) at 630 nm.
Invasion assay
Boyden chamber (Neuro Probe Inc., Gaithersburg, MD,
USA) was used to evaluate the spontaneous invasion
of NCI-H460 cells as previously described [34]. The
method is based on the passage of cells across porous
filters separating the upper and lower wells of the mi-
gration chamber using OPN (50 nM) treated NCI-H
460 cells. Polyvinyl-pyrrolidone-free polycarbonate fil-
ters (8 μm pore size) were used in this experiment. The
filters were coated with the reconstituted basement
membrane Matrigel (50 μg/filter). NCI-H460 cells were
pre-cultured in FBS free-Dulbecco’s Modified Eagle
Medium (DMEM) in the absence or presence of EEOS
for 7 h and then were loaded onto the upper compart-
ment of the Boyden chamber with various concentrations
of EEOS (100 and 200 μg/ml). FBS free Minimum Essential
Medium (MEM) containing 0.1% BSA was placed in the
lower compartment of the Boyden chamber. The migration
was allowed to occur in the absence (control condition) or
presence of EEOS in the medium of the upper and the
lower compartment of the migration chamber. The cham-
ber was incubated at 37°C for 7 h and the filters were re-
moved and fixed in methanol. Non-migrated cells on the
upper surface of the filter were removed with a cotton
swab, while migrated cells, adherent on the lower filter sur-
face, were stained with Diff-Quick (Mertz-Dade AG, Dade
International, Milan, Italy) and counted under a light
microscope (×400 in 10 random fields) per each well. Each
experiment was performed in triplicates. Migration values
were expressed as means ± S.D. of the number of migrated
Figure 1 The cytotoxicity of EEOS on NCI-H460. Cells were
treated with 0, 6, 12.5, 25, 50, 100 or 200 μg/ml of EEOS for 24 h.
Cell viability was determined by the MTT assay. Data represent
means ± S.D. The cytotoxicity of EEOS was weak up to 200 μg/ml in
NCI-H460 cells.
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Western blotting
Whole cell lysates from OPN (50 nM) treated cells
exposed to EEOS for 24 h were prepared using lysis
buffer (50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 0.5%
Triton X-100, 5 mM EDTA, 1 mM Na3VO4, 1 mM
NaF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml
pepstatin, 10 mM iodoacetamide, 2 mM PMSF). Nuclear
protein extracts and cytoplasmic protein extracts were
collected by using NE-PER nuclear and cytoplasmic ex-
traction reagents (Thermo scientific, Rockford, IL). The
protein contents were measured by using a Bio-Rad DC
protein assay kit II (Bio-Rad, Hercules, CA), separated
on 10% tris-glycin gels, and electrotransferred onto a
Hybond ECL transfer membrane with transfer buffer
(25 mM Tris, 250 mM glycine, 20% methanol). The
membranes were blocked in 5% nonfat dry milk in TBS
buffer containing 0.1% Tween 20 (TBST) and immuno-
blotted with antibodies of PI3K, p-AKT, OPN, CD44
(Cell signaling, USA).
ELISA for VEGF & MMP-9 activity
The level of VEGF in NCI-H460 cells was measured
with a commercially available ELISA kit (R&D systems,
Minneapolis, MN). Briefly, the cells were starved for 6 h
in M199 containing 5% FBS and then treated with bFGF
(50 ng/ml) containing EEOS (50, 100 and 200 μg). After
48 h incubation, the supernatant was individually col-
lected and measured by ELISA kit.
MMP-9 enzymatic activities were assayed by ELISA
Kit for MMP-9 (Invitrogen, Camarillo, CA, USA) [35].
NCI-H460 cells plated on 6-well plates were grown to
90% confluence in 2 ml of growth medium in the pres-
ence of OPN (50 nM). The cells were maintained in
serum-free media and treated with various concentra-
tions of EEOS for 24 h. Conditioned medium was col-
lected and analyzed for the activity of MMP-9 using
Human MMP-9 ELISA kit, according to the manufac-
ture’s protocol. Also, PI3K/AKT inhibitor LY294002 study
was performed for MMP-9 activity affected by EEOS in
OPN treated NCI-H460 cells.
RT-PCR analysis
Total RNA from OPN (50 nM) treated cells exposed to
EEOS for 24 h was isolated using the Trizol reagent ac-
cording to the manufacturer’s instructions (Invitrogen,
Carsbad, CA). One microgram of total RNA was con-
verted to cDNA by Superscript reverse transcriptase and
amplified by Platinum Taq polymerase using Superscript
One Step RT-PCR kit (Invitrogen, Carsbad, CA, USA).
Primers were synthesized by Bioneer (Daejeon, Korea)
with the following sequences: forward 5′-ACATTCACTGGTGCAACTGC-3′ and reverse 3′-CAAGCGTGT
CAGCGCTGTAG-5′ for uPA; forward 5′-ATCAGA
CATGAGCTGTGAGAGG-3′ and reverse 5′-ACTACG
GCTCTGAAGTCACCAC-3′ for uPAR; forward 5′-AT
GCCCG-CATTAGCTCTTAG-3′ and reverse 5′-GCAA
CTTCCCAAAATGTGCC-3′ for EGFR; forward 5′-TC
ACCATCTTCCAGGAGCGA-3′; reverse, 5′-CACAA
TGCCGAAGTGGTCGT-3′ for GAPDH primers. PCR
conditions comprised an initial step at 50°C for 30 min,
94°C for 2 min, followed by 30 cycles at 94°C for 15 s,
55°C for 30 s and 72°C for 1 min, and a final step at
72°C for 10 min. The amplified products were separated
on 2% agarose gel. Also, PI3K/Akt inhibitor LY294002
study was performed for uPA affected by EEOS in OPN
treated NCI-H460 cells.
Statistical analysis
All data were presented as means ± standard deviation
(S.D.). A one-way ANOVA was used for comparison of
multiple groups. Student’s t-test was used for com-
parison of two groups. Statistical difference was set at
p values of <0.05 between control and EEOS-treated
groups.
Results
Effect of EEOS on the viability of NCI-H460 cells
To evaluate cytotoxic effect of EEOS, MTT assay was
performed. NCI-H460 cells were plated in 96-well plate
and treated with various concentrations (0, 6, 12.5, 25,
50, 100, and 200 μg/ml) of EEOS for 24 h. As shown in
Figure 1, the cytotoxicity of EEOS was weak up to
200 μg/ml in NCI-H460 cells. Thus, the next metastasis
related experiments were carried out at the concentra-
tions below 200 μg/ml.
Kwak et al. BMC Complementary and Alternative Medicine 2014, 14:419 Page 4 of 10
http://www.biomedcentral.com/1472-6882/14/419Effects of EEOS on the adhesion and invasion of
NCI-H460 cells
The first step of metastasis is the adhesion of cancer
cells to extracellular matrix (ECM) [36]. To evaluate
the adhesive ability of NCI-H460 cells, the cells treated
with or without EEOS were added onto Matrigel
coated plates. As shown in Figure 2, EEOS signifi-
cantly inhibited the number of cell adhesion from
100 μg/ml in untreated or OPN treated NCI-H460 cells
compared to untreated control. Similarly, EEOS signifi-
cantly suppressed the number of invaded cells by inva-
sion assay using Boyden-chamber compared to untreated
control in untreated or OPN treated NCI-H460 cells
(Figure 3).Figure 2 Inhibitory effect of EEOS on adhesion ability of NCI-H460 ce
presence of OPN (50 nM) on the adhesion to Matrigel coated plate aft
crystal violet staining (A) and were quantified (B). The values represent mea
***, p < 0.001, vs untreated control.Effects of EEOS on metastasis related molecules in OPN
treated or untreated NCI-H460 cells
OPN [9,37] and CD44 [38,39] are closely involved in
metastasis process. Western blotting revealed that EEOS
downregulated the expression of OPN and CD44 in
NCI-H460 cells (Figure 4A) and also suppressed the
expression of CD44 in OPN treated NCI-H460 cells
(Figure 4B).
Our study showed that EEOS attenuated the expres-
sion of PI3K and COX-2 and the phosphorylation of
Akt at protein level in OPN treated NCI-H460 cells
(Figure 4C). Also, EEOS attenuated the expression of
PI3K and the phosphorylation of Akt at protein level in
OPN treated NCI-H460 cells (Figure 4D).lls mediated by osteopontin. Effect of EEOS in the absence or
er 20 min exposure. Attached cells were photographed (×200) after
ns ± S.D. of 3 different experiments performed in triplicates. ** , p < 0.01,
Figure 3 Inhibitory effect of EEOS on invasion ability of NCI-H460 cells mediated by osteopontin. Effect of EEOS in the absence or
presence of OPN (50 nM) on the invasion ability of NCI-H460 cells. The cells pretreated for 7 h with or without EEOS (0, 100 or 200 μg/ml), were
placed in the upper well of the migration chamber and incubated at 37°C for 6 h. The filter was then removed and fixed in methanol. At the end
of incubation, images of a number of invaded cells were taken under a light microscope per each field (A) and finally quantified (B). *Statistically
significant value compared with control data (**p < 0.01).
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plays a key role in metastasis [40,41]. ELISA showed that
EEOS significantly reduced VEGF production in NCI-
H460 cells (Figure 4E).
There are evidences that uPA [12,42], uPAR [13] and
EGFR [43,44] are closely involved in metastasis. In the
current study, RT-PCR analysis exhibited that EEOSattenuated the expression of uPA, uPAR and EGFR in
NCI-H460 cells (Figure 5A). Additionally, EEOS attenu-
ated the expression of uPA in OPN treated NCI-H460
cells (Figure 5B). ELISA revealed that EEOS significantly
reduced MMP-9 activity in NCI-H460 cells (Figure 5C).
Also, PI3K/Akt inhibitor LY294002 enhanced anti-
metastatic potential of EEOS to attenuate the expression
Figure 4 Effects of EEOS on downregulation of OPN and CD44 and suppression of PI3K/Akt, COX-2 and VEGF in OPN treated NCI-H460.
(A) Effect of EEOS on expression of osteopontin or CD44 in NCI-H460 cells exposed to EEOS for 24 h and Western blotting was performed
with antibodies of OPN and CD44. (B) Effect of EEOS with treatment of OPN on expression of CD44 in NCI-H460 cells. Western blotting
was performed with antibodies of CD44. (C) Effect of EEOS on expression of PI3K, COX-2 and the phosphorylation of Akt in NCI-H460 cells.
(D) Effect of EEOS with treatment of OPN for 30 min or 24 h on expression of PI3K, and the phosphorylation of Akt in OPN treated NCI-H460
cells. (E) Effect of EEOS on VEGF production in NCI- H460 cells. The level of VEGF in NCI-H460 cells was measured by ELISA. *P < 0.05, **P < 0.01,
versus control.
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(Figure 6). EEOS and LY294002 attenuated the expres-
sion of PI3K/Akt signaling in OPN treated NCI-H460
(Figure 6A). EEOS and LY294002 attenuated the mRNA
expression of uPA (Figure 6B) as well as MMP-9 activity
in OPN treated NCI-H460 (Figure 6C).
Discussion
Though modern medicine has contributed to the treatment
of cancers by surgery, chemotherapy and radiotherapyfor years, metastasis frequently shown in the patients
with malignant neoplasms is still the leading cause of
death in cancer patients [45,46].
Metastasis processes are closely associated with tumor
cell dissociation, arrest in small vessels, adhesion to
endothelial cells, extravasation, neovascularization, inva-
sion of the target organ, and proliferation [1,2]. Non-
small cell lung carcinomas (NSCLCs), one of epithelial
lung cancers, are relatively insensitive to chemotherapy
compared with small cell lung carcinoma. A549 and
Figure 5 Effect EEOS on the expression of uPA, uPAR and EGFR in NCI-H460 cells. (A) RT-PCR analysis showed that EEOS attenuated
the expression of uPA, uPAR and EGFR in NCI-H460 cells. (B) Effect EEOS on the mRNA expression of uPA in OPN treated NCI-H460 cells.
(C) Effect EEOS on MMP-9 activity in NCI-H460 cells by ELISA.
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wild type [47]. Thus, our study focused the underlying
anti-metastatic mechanism of EEOS in OPN treated
NCI-H460 NSCLCs, since OPN plays a critical role in
metastasis [7,37].
Adhesion and invasion assays showed that EEOS sig-
nificantly inhibited cell adhesion and invasion in OPN
treated and non treated NCI-H 460 cells, implying
that EEOS can suppress OPN mediated metastasis in
NSCLCs. There are evidences that OPN and CD 44 play
critical roles in metastatic processes [7,37,39]. Western
blotting revealed that EEOS effectively attenuated the ex-
pression of OPN and CD44 and also OPN activated CD44
at nontoxic concentrations in NCI-H460 cells.
It was well documented that phosphatidylinositide 3-
kinases (PI3K)/Akt [48,49] and cyclooxygenase 2 (COX-2)[50,51] are closely associated with metastasis. Here, EEOS
effectively suppressed the expression of PI3K and COX-2
and the phosphorylation of Akt at protein level in OPN
treated NCI-H460 cells, indicating that inhibition of PI3K/
Akt and COX-2 pathway mediates anti-metastatic effect of
EEOS in NCI-H460 cells.
MMPs play important roles in tumor metastasis [52,53].
As expected, EEOS significantly attenuated the expression
of uPA, its receptor uPAR and EGFR in NCI-H460 cells
by RT-PCR, reduced VEGF production by ELISA and sup-
pressed MMP-9 expression by ELISA in NCI-H460 cells,
implying the involvement of uPA/MMP-9/VEGF signal-
ing. Conversely, PI3K/Akt inhibitor LY294002 enhanced
anti-metastatic potential of EEOS to attenuate the expres-
sion of uPA and MMP-9 in OPN treated NCI-H 460
cells, demonstrating that inhibition of PI3K/Akt signaling
Figure 6 Effect of PI3K inhibitor LY294002 on PI3K signaling and MMP-9 activity in OPN treated NCI-H460 cells. (A) Effect of EEOS and
LY294002 on PI3K/Akt signaling in OPN treated NCI-H460. (B) Effect of EEOS and LY294002 on uPA expression in OPN treated NCI-H460
by RT-PCR. (C) Effect of EEOS and LY294002 on MMP-9 activity in OPN treated NCI-H460 by ELISA. Values represent means ± S.D. *P < 0.05,
**P < 0.01, versus untreated control.
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H 460 cells.
Conclusions
In summary, EEOS significantly inhibited cell adhesion
and invasion at nontoxic concentrations, attenuated the
expression of OPN and CD44 and also OPN activated
CD44 in NCI-H460 cells. In addition, EEOS effectivelysuppressed PI3K/Akt, COX-2, uPA, uPAR, MMP-9, VEGF
and EGFR in OPN treated NCI-H460 cells. Conversely,
PI3K/Akt inhibitor LY294002 enhanced anti-metastatic po-
tential of EEOS to attenuate the expression of uPA and
MMP-9 in OPN treated NCI-H 460 cells. Taken together,
these findings suggest that inhibition of PI3K/Akt mediates
OPN enhanced metastasis in Ocimum sanctum treated
NCI-H460 non- small cell lung cancer cells.
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